Acquisition of Nebido^®

One in six men over 50 live with symptomatic androgen deficiency¹. However, only one in ten men between the age of 30 to 79 with symptomatic androgen deficiency receive treatment². The condition is caused by a reduced or absent secretion of testosterone from the testes.

Nebido^® is a well-known brand in testosterone therapy. The product is directly administered by a physician every 10-14 weeks. Nebido^® demonstrated a robust safety and efficacy profile backed with solid long-term data.

Nebido^® is approved and successfully commercialised in over 80 countries. Patent protection exists until March 2024 in the EU and until May 2027 in the US.

^{1 Araujo, A. B., Esche, G. R., Kupelian, V., O’Donnell, A. B., Travison, T. G., Williams, R. E., ... & McKinlay, J. B. (2007). Prevalence of symptomatic androgen deficiency in men. The Journal of Clinical Endocrinology & Metabolism, 92(11), 4241-4247
2 Hall, S. A., Araujo, A. B., Esche, G. R., Williams, R. E., Clark, R. V., Travison, T. G., & McKinlay, J. B. (2008). Treatment of symptomatic androgen deficiency: results from the Boston Area Community Health Survey. Archives of internal medicine, 168(10), 1070-1076.}